Skip to main content

Advertisement

Table 5 Health state utilities used in the model

From: Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Utility state Utility values used in base case (literature) Values used in scenario analysis (TTO) Reference (literature values) Data source
Induction treatmenta 0.648 0.162 Uyl-de Groot et al. 1998 [18] Measured EQ-5D
Consolidation treatmenta 0.710 0.568 Batty et al. 2014 [19] Calculated from published literature
Monotherapy treatmenta 0.810 0.889 Batty et al. 2014 [19] Calculated from published literature
Complete remission 0.830 0.887 Leunis et al. 2014 [29] Measured EQ-5D
Relapse 0.530 0.505 Pan et al. 2010 [30] Mapped from QLQ-C30
SCT treatmenta 0.613 − 0.210 Source for algorithm—Crott et al. 2010 [27]; Source of QLQC30 data—Grulke et al. 2012 [28] Mapped from QLQ-C30
SCT recovery 0.810 0.748 Source for algorithm—Crott et al. 2010 [27]; Source of QLQC30 data—Grulke et al. 2012 [28] Mapped from QLQ-C30
Post-SCT recovery 0.826 0.715 Source for algorithm—Crott et al. 2010 [27]; Source of QLQC30 data—Grulke et al. 2012 [28] Mapped from QLQ-C30
  1. TTO time trade-off, STC stem cell transplantation, QLQC30 Quality of Life Questionnaire Core 30 (produced by the European Organization for Research and Treatment of Cancer)
  2. aIncludes treatment disutility